EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of white matter hyperintensities with long‐term EGFR‐TKI treatment and prediction of progression risk

Hang Yang, Rui Meng, Junjie Jiang, Yan Luo, Xiaolin Deng, Sibo Yang, Shengcai Chen, Jiehong Wu, Yan Wan, Yanan Li, Huijuan Jin, Quanwei He und 5 weitere

Brain and Behavior · 2023

DOI: 10.1002/brb3.3326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Behavior, 2023. Verfasst von Hang Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, White Matter. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The purpose of this study was to test the hypothesis that brain white matter hyperintensities (WMH) are more common in patients receiving epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) and identify clinical risk factors associated with WMH. Experimental design This multiple‐center, prospective cohort study was conducted from March 2017 to July 2020. Two groups of patients with non‐small cell lung cancer (NSCLC) who received or did not receive EGFR‐TKI were included and followed up for more than 24 months. The progression of WMH was defined as an increase of ≥1 point on the Fazekas visual rating scale between the baseline and at the 2‐year follow‐up. A modified Poisson regression model was performed to evaluate risk factors on increased WMH load.

Results

Among 286 patients with NSCLC, 194 (68%) patients with NSCLC who received EGFR‐TKI and 92 (32%) patients with NSCLC without EGFR‐TKI treatment were analyzed. Modified Poisson regression analysis showed that EGFR‐TKI treatment was independently associated with the WMH progression (EGFR‐TKI: aRR 2.72, 95% confidence interval [CI] 1.46–5.06, p = .002). Interleukin (IL)‐2, IL‐4, and IL‐10 were associated with increased WMH in the adjusted model (IL‐2: aRR 1.55 [95% CI 1.06–2.25], p = .023; IL‐4: aRR 1.66 [95% CI 1.13–2.43], p = .010; IL‐10: aRR 1.48 [95% CI 1.06–2.06], p = .020).

Conclusion

Patients with NSCLC who received EGFR‐TKI may be at higher risk of developing WMH or worsening of WMH burden. The impact of increased WMH lesions in these patients is to be further assessed. IL‐2, IL‐4, and IL‐10 may be used as potential biomarkers to monitor the risk of increased WMH burden

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsWhite MatterHumansInterleukin-2Interleukin-10Prospective StudiesInterleukin-4Protein Kinase InhibitorsErbB ReceptorsMutationRetrospective Studies

Stichwörter der Autor:innen

epidermal growth receptor-tyrosine kinase inhibitornon-small cell lung cancerwhite matter hyperintensities

Substanzen

Interleukin-2Interleukin-10Interleukin-4Protein Kinase InhibitorsErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Neurovascular Division, Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
  • Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Bo Hu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hubei Province of China

Zitieren

APA

Yang, H., Meng, R., Jiang, J., Luo, Y., Deng, X., Yang, S., Chen, S., Wu, J., Wan, Y., Li, Y., Jin, H., He, Q., Wang, D., Chang, J., Yang, K., Zhou, Y., & Hu, B. (2023). Association of white matter hyperintensities with long‐term EGFR‐TKI treatment and prediction of progression risk. Brain and Behavior. https://doi.org/10.1002/brb3.3326

Vancouver

Yang H, Meng R, Jiang J, Luo Y, Deng X, Yang S, et al. Association of white matter hyperintensities with long‐term EGFR‐TKI treatment and prediction of progression risk. Brain and Behavior. 2023. doi:10.1002/brb3.3326

BibTeX
@article{Yang2023,
  author = {Yang, Hang and Meng, Rui and Jiang, Junjie and Luo, Yan and Deng, Xiaolin and Yang, Sibo and Chen, Shengcai and Wu, Jiehong and Wan, Yan and Li, Yanan and Jin, Huijuan and He, Quanwei and Wang, David and Chang, Jiang and Yang, Kunyu and Zhou, Yifan and Hu, Bo},
  title = {Association of white matter hyperintensities with long‐term EGFR‐TKI treatment and prediction of progression risk},
  journal = {Brain and Behavior},
  year = {2023},
  doi = {10.1002/brb3.3326}
}
Kostenlos starten →